Abhinav Vasudevan, Nina Parthasarathy, Danny Con, Steven Nicolaides, Ross Apostolov, Ayushi Chauhan, Maria Bishara, Raphael P Luber, Neetima Joshi, Anna Wan, James A Rickard, Tony Long, Declan Connoley, Miles P Sparrow, Peter R Gibson, Daniel R van Langenberg
BACKGROUND: There are safety concerns regarding immunomodulators (thiopurines and methotrexate) for treatment of inflammatory bowel disease (IBD). AIM: To compare the long-term tolerability, and persistence of thiopurine and methotrexate therapy in IBD. METHODS: A retrospective cohort study was performed at two hospitals between 1 January 2004 and 31 December 2016 for patients commenced on thiopurines or methotrexate for IBD. Treatment discontinuation rates, intolerances and disease activity were obtained from medical records...
October 2020: Alimentary Pharmacology & Therapeutics